Targeted therapy pralsetinib safely effectively treats lung and thyroid cancers with RET alterations
Results from the multi-cohort Phase I/II ARROW clinical trial, conducted by The University of Texas MD Anderson Cancer Center researchers, showed that a once-daily dose of pralsetinib, a highly selective RET inhibitor, was ...
Jun 10, 2021
0
1